Stocks · News reference

Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53

Aug 5, 2026, 6:51 PMBenzinga Newsdesk

Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 22, 2026, 12:00 PMResearchandmarkets.Com
Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities
The global metabolomics market is projected to grow from USD 2.81 billion in 2025 to USD 9.01 billion by 2035, expanding at a CAGR of 12.36%. Growth is driven by precision medicine, biomarker discovery, and multiomics adoption, with oncology accounting for over 44% of the market. However, Q1 2026 faced challenges from geopolitical tensions, supply chain disruptions, and elevated logistics costs affecting laboratory budgets and procurement timelines.
A TMO BRKR BRKRP BIO
BenzingaSep 21, 2026, 11:08 AMBenzinga Newsdesk
Bruker Wins Major UC Berkeley Order For Advanced Research Systems
Bruker Corporation (NASDAQ:BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center.
BRKR
BenzingaSep 16, 2026, 1:57 PMAvi Kapoor
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
ALVO AXTI BBNX BRKR CIFR
BenzingaSep 9, 2026, 5:43 PMBenzinga Newsdesk
UBS Maintains Neutral on Bruker, Raises Price Target to $65
BRKR